ProfileGDS5678 / 1424696_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 76% 78% 78% 79% 75% 78% 73% 78% 78% 76% 77% 76% 75% 77% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.0184976
GSM967853U87-EV human glioblastoma xenograft - Control 25.401778
GSM967854U87-EV human glioblastoma xenograft - Control 35.4467978
GSM967855U87-EV human glioblastoma xenograft - Control 45.703979
GSM967856U87-EV human glioblastoma xenograft - Control 54.9587875
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.2001178
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.641173
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.3715278
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.3586478
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.1213876
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.2161977
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.1824176
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.9543575
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.1902177